{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:06:28Z","timestamp":1754161588733,"version":"3.41.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1023\/b:ddas.0000020504.41500.9c","type":"journal-article","created":{"date-parts":[[2004,3,20]],"date-time":"2004-03-20T10:25:32Z","timestamp":1079778332000},"page":"462-465","source":"Crossref","is-referenced-by-count":7,"title":["CASE REPORT: Toxic Hepatitis After Sequential Administration of Flutamide and Cyproterone Acetate"],"prefix":"10.1007","volume":"49","author":[{"given":"Spilios","family":"Manolakopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotirios","family":"Bethanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Armonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalis","family":"Economou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec","family":"Avgerinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Tzourmakliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"5","key":"486399_CR1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003088-198712050-00001","volume":"12","author":"JG Ridell","year":"1987","unstructured":"Ridell JG, Harron DW, Shanks RG: Clinical pharmacokinetics of beta-adrenoreceptor antagonists. An update. Clin Pharmacokinet 12(5):305-320, 1987","journal-title":"Clin Pharmacokinet"},{"issue":"8Suppl","key":"486399_CR2","first-page":"28","volume":"2","author":"U Borchard","year":"1990","unstructured":"Borchard U: Pharmacokinetics of beta-adrenoreceptor blocking agents: Clinical significance of hepatic and\/or renal clearance. Clin Phys Biochem 8 (Suppl)2:28-34, 1990","journal-title":"Clin Phys Biochem"},{"key":"486399_CR3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","volume":"321","author":"ED Crawford","year":"1989","unstructured":"Crawford ED, Eisenberger MA, McLeod DG, et al.: A conrolled trial of leuprorelide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989","journal-title":"N Engl J Med"},{"key":"486399_CR4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0015-0282(16)55701-X","volume":"59","author":"A Friedman","year":"1993","unstructured":"Friedman A, Narcross MJ, Rein M: Adverse effects of leuprorelide acetate depot treatment. Fertil Steril 59:448-450, 1993","journal-title":"Fertil Steril"},{"issue":"5","key":"486399_CR5","first-page":"293","volume":"71","author":"R Migliari","year":"1999","unstructured":"Migliari R, Muscas G, Murru M, et al.: Antiandrogens: A summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 71(5):293-302, 1999","journal-title":"Arch Ital Urol Androl"},{"key":"486399_CR6","first-page":"465","volume":"92","author":"JL Gomez","year":"1992","unstructured":"Gomez JL, Dupont A, Cusan L, et al.: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Isr J Med 92:465-470, 1992","journal-title":"Isr J Med"},{"key":"486399_CR7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-118-11-199306010-00006","volume":"118","author":"D Wysowski","year":"1992","unstructured":"Wysowski D, Freiman JP, Tourtelot JP, et al.: Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118:860-864,1992","journal-title":"Ann Intern Med"},{"issue":"7","key":"486399_CR8","first-page":"419","volume":"93","author":"M Garcia Cortes","year":"2001","unstructured":"Garcia Cortes M, Andrade RJ, Lucena MI, et al.: Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig 93(7):419-422, 2001","journal-title":"Rev Esp Enferm Dig"},{"key":"486399_CR9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0168-8278(94)80006-5","volume":"20","author":"S Dourakis","year":"1994","unstructured":"Dourakis S, Alexopoulou A, Hadziyannis S: Fulminant hepatitis after flutamide treatment. J Hepatol 20:350-353, 1994","journal-title":"J Hepatol"},{"issue":"3","key":"486399_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/096032719901800301","volume":"18","author":"M Cetin","year":"1999","unstructured":"Cetin M, Demirci D, Unal A, et al.: Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18(3):137-140, 1999","journal-title":"Hum Exp Toxicol"},{"issue":"4","key":"486399_CR11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000474216","volume":"30","author":"A Hinkel","year":"1996","unstructured":"Hinkel A, Berges RR, Pannek J, et al.: Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long\u2013term follow up of 89 patients. Eur Urol 30(4):464-470, 1996","journal-title":"Eur Urol"},{"key":"486399_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(89)91225-7","volume":"I","author":"H Levesque","year":"1989","unstructured":"Levesque H, Trivalle C, Manchon ND, et al.: Fulminant hepatitis due to cyproterone acetate. Lancet I:215-216, 1989","journal-title":"Lancet"},{"key":"486399_CR13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1464-410X.1991.tb15142.x","volume":"67","author":"BT Parys","year":"1991","unstructured":"Parys BT, Hamid S, Thomson RGN: Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 67:312-313, 1991","journal-title":"Br J Urol"},{"key":"486399_CR14","first-page":"238","volume":"30","author":"D Hirsch","year":"1994","unstructured":"Hirsch D, Kovatz S, Bernheim J, et al.: Fatal fulminant hepatitis from cyproterone acetate. Isr J Med Sci 30:238-242, 1994","journal-title":"Isr J Med Sci"},{"issue":"2","key":"486399_CR15","first-page":"153","volume":"49","author":"L Bressolette","year":"1994","unstructured":"Bressolette L, Dubois A, Carlhant D, et al.: Fatal hepatitis caused by cyproterone acetate. Therapie 49(2):153, 1994","journal-title":"Therapie"},{"issue":"7","key":"486399_CR16","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1023\/A:1026639432428","volume":"44","author":"G Friedman","year":"1999","unstructured":"Friedman G, Lamoureux E, Sherker A: Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 44(7):1362-1363, 1999","journal-title":"Dig Dis Sci"},{"key":"486399_CR17","first-page":"99","volume-title":"Liver biopsy interpetation","author":"PJ Scheuer","year":"1988","unstructured":"Scheuer PJ: Liver biopsy interpetation, 4th ed. Philadelphia, Bailliere Tindall, 1988, pp 99-112","edition":"4th ed."},{"issue":"8","key":"486399_CR18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1046\/j.1365-2036.1999.00596.x","volume":"13","author":"M Trauner","year":"1999","unstructured":"Trauner M, Graziadei IW: Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13(8):979-996, 1999","journal-title":"Aliment Pharmacol Ther"},{"key":"486399_CR19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/00007890-199105000-00041","volume":"51","author":"B Kallinowski","year":"1991","unstructured":"Kallinowski B, Theilmann L, Zimmermann R, et al.: Effective treatment of cyclosporine\u2013induced cholestasis in heart\u2013transplanted patients treated with ursodeoxycholic acid. Transplantation 51:1128-1129, 1991","journal-title":"Transplantation"},{"issue":"11","key":"486399_CR20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/BF02071403","volume":"41","author":"C Cicognani","year":"1996","unstructured":"Cicognani C, Malavolti M, Morselli\u2013Labate A, et al.: Flutamide\u2013induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 41(11):2219-2221, 1996","journal-title":"Dig Dis Sci"},{"issue":"7","key":"486399_CR21","first-page":"523","volume":"90","author":"A Soza","year":"1998","unstructured":"Soza A, Riquelme F, Alvarez M, et al.: Hepatotoxicity by amoxycillin\/clavulanic acid: case report. Rev Esp Enferm Dig 90(7):523-526, 1998","journal-title":"Rev Esp Enferm Dig"},{"issue":"7","key":"486399_CR22","first-page":"523","volume":"90","author":"J Barrio","year":"1998","unstructured":"Barrio J, Castiella A, Lobo C, et al.: Cholestatic acute hepatitis induced by amoxycillin\u2013clavulanic acid combination. Role of ursodeoxycholic acid in drug\u2013induced cholestasis. Rev Esp Enferm Dig 90(7):523-526, 1998","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"486399_CR23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00042737-200012030-00017","volume":"12","author":"P Katsinelos","year":"2000","unstructured":"Katsinelos P, Vasiliadis T, Xiarchos P, et al.: Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin\u2013clavulanate potassium (Augmentin)\u2013induced intra\u2013hepatic cholestasis: Report of two cases. Eur J Gastroenterol Hepatol 12(3):365-368, 2000","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"36","key":"486399_CR24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1055\/s-2007-1024477","volume":"124","author":"W Habscheid","year":"1999","unstructured":"Habscheid W, Abele U, Dahm HH: Severe cholestasis with kidney failure from anabolic steroids in a body builder. Dtsch Med Wochenschr 124(36):1029-1032, 1999","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"486399_CR25","first-page":"29","volume":"56","author":"L Salmon","year":"2001","unstructured":"Salmon L, Montet JC, Oddoze C, et al.: Ursodeoxycholic acid and prevention of tacrine\u2013induced hepatotoxicity: a pilot study. Therapie 56(1):29-34, 2001","journal-title":"Therapie"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DDAS.0000020504.41500.9c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/B:DDAS.0000020504.41500.9c\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DDAS.0000020504.41500.9c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:13:24Z","timestamp":1753758804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/B:DDAS.0000020504.41500.9c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["486399"],"URL":"https:\/\/doi.org\/10.1023\/b:ddas.0000020504.41500.9c","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}